GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kura Oncology Inc (NAS:KURA) » Definitions » FCF Yield %

KURA (Kura Oncology) FCF Yield % : -22.60 (As of Dec. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kura Oncology FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Kura Oncology's Trailing 12-Month Free Cash Flow is $-169.24 Mil, and Market Cap is $748.87 Mil. Therefore, Kura Oncology's FCF Yield % for today is -22.60%.

The historical rank and industry rank for Kura Oncology's FCF Yield % or its related term are showing as below:

KURA' s FCF Yield % Range Over the Past 10 Years
Min: -23.01   Med: 0   Max: 0
Current: -22.6


KURA's FCF Yield % is ranked worse than
60.92% of 1507 companies
in the Biotechnology industry
Industry Median: -12.96 vs KURA: -22.60

Kura Oncology's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.


Kura Oncology FCF Yield % Historical Data

The historical data trend for Kura Oncology's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kura Oncology FCF Yield % Chart

Kura Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.78 -3.33 -11.34 -13.06 -11.69

Kura Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.16 -12.84 -12.04 -10.82 -11.44

Competitive Comparison of Kura Oncology's FCF Yield %

For the Biotechnology subindustry, Kura Oncology's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kura Oncology's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Kura Oncology's FCF Yield % falls into.



Kura Oncology FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Kura Oncology's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-124.992 / 1069.153
=-11.69%

Kura Oncology's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-43.44 * 4 / 1519.21546
=-11.44%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kura Oncology FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Kura Oncology FCF Yield % Related Terms

Thank you for viewing the detailed overview of Kura Oncology's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kura Oncology Business Description

Traded in Other Exchanges
Address
12730 High Bluff Drive, Suite 400, San Diego, CA, USA, 92130
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Executives
Kathleen Ford officer: Chief Operating Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Teresa Brophy Bair officer: Chief Legal Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Stephen Dale officer: Chief Medical Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thomas James Doyle officer: SVP, Finance & Accounting C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Troy Edward Wilson director, officer: President and CEO C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Brian T. Powl officer: Chief Commercial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Thomas Malley director C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Kirsten Flowers officer: Chief Commercial Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Helen Louise Collins director TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Carol Schafer director 42 WHITE STREET, FOURTH FLOOR, NEW YORK NY 10013
Marc Grasso officer: CFO, CBO C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Bridget A Martell officer: Acting Chief Medical Officer C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Basta officer: Chief Legal Officer C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Antonio Gualberto officer: Chief Medical Officer 245 FIRST STREET, SUITE 1820, CAMBRIDGE MA 02142